SCHEMBL5886944

SCHEMBL5886944

CSc1nc(C)c2ccc(=O)n(-c3ccc(C(=O)O)cc3)c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.47
MAPK1 P28482 2/20 0.43
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 4/20 0.42
KDM4E B2RXH2 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
MEN1 O00255 3/20 0.42
POLB P06746 3/20 0.42
MAPT P10636 3/20 0.42
HPGD P15428 1/20 0.42
APEX1 P27695 1/20 0.42
HTT P42858 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HSD17B10 Q99714 1/20 0.38
PABPC1 P11940 1/20 0.38
NR4A1 P22736 1/20 0.38
NR4A2 P43354 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886919 0.89 RXRA (0.37) RXRAMAPK1ALDH1A1KMT2AKDM4E
SCHEMBL5886794 0.84 POLB (0.34) RXRAMAPK1ALDH1A1KMT2AMEN1
SCHEMBL5886795 0.82 MAPT (0.46) ALDH1A1KMT2ATDP1MEN1POLB
SCHEMBL5886798 0.75 RXRA (0.47) RXRAMAPK1ALDH1A1KMT2APOLB
SCHEMBL5887252 0.74 PARP10 (0.45) RXRAMAPK1ALDH1A1KMT2AKDM4E
SCHEMBL5886774 0.74 NPC1 (0.46) RXRAMAPK1ALDH1A1KMT2AMEN1
SCHEMBL5887058 0.74 TSHR (0.34) RXRAALDH1A1KMT2AKDM4EMEN1
SCHEMBL5886930 0.74 MEN1 (0.44) RXRAMAPK1ALDH1A1KMT2AKDM4E
SCHEMBL5886741 0.71 LMNA (0.42) RXRAALDH1A1KMT2AMEN1POLB
SCHEMBL5887001 0.71 MEN1 (0.51) ALDH1A1KMT2AKDM4EMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP RXRA 3986/4885MAPK1 855/4885ALDH1A1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.